Viread

Notice and Comment

In the matter of the Patent Act R.S.C. 1985, c. P-4, as amended
AND IN THE MATTER OF Gilead Sciences, Inc.
AND IN THE MATTER OF Viread (tenofovir disoproxil fumarate)

The Patented Medicine Prices Review Board (Board) is proposing to issue an Advance Ruling Certificate (ARC) pursuant to subsection 98(4) of the Patent Act in respect of the price of the patented medicine Viread.

Here are the Notice and Comment and the proposed Advance Ruling Certificate.

Persons who wish to make representations in this matter shall file a written submission with the Board on or before May 7, 2004. The Board will consider all submissions by the provincial and territorial Ministers of Health. All submissions by other persons shall include a clear statement of the person's interest in this matter, and shall state the reasons why the Board should consider the submission. All submissions shall be filed with the Secretary of the Board, at:

Box L40
333 Laurier Avenue West
Suite 1400
Ottawa, Ontario
K1P 1C1

Or by e-mail at:
sdupont@pmprb-cepmb.gc.ca

Board Staff and Gilead Sciences, Inc. will be given the opportunity to make written submissions in response to any written submissions received no later than May 25, 2004.

Further information on the role and process of the Board may also be obtained from the Secretary of the Board by calling the PMPRB's toll-free line: 1 877 860-2150 or (613) 954-8299.